ReviewClinical microbiology reviews2016
Modulation of Host Immunity by the Human Metapneumovirus.
Review in Clinical microbiology reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 50 citations in OpenAlex.
- Review
- Human pneumovirus induces IFN-dependent expression of the immune-responsive gene 1 and is inhibited by 4-octyl itaconate in human macrophages.NAR molecular medicine · 2026Article
- Review
- Human Metapneumovirus (HMPV): A comprehensive review of its virology, epidemiology, clinical features, and advances in diagnosis and prevention.Northern clinics of Istanbul · 2026Review
- Human Metapneumovirus Nucleocapsid Inhibitors Discovery for Targeting Viral Replication and Genome Encapsidation: An In Silico Approach.Journal of tropical medicine · 2026Article
- Advances in Human Metapneumovirus Research: Clinical Impact, Diagnostic Innovations, and Therapeutic Challenges.Pathogens (Basel, Switzerland) · 2025Review
- hMPV co-infections: Distinct immunopathogenic mechanisms and clinical implications of viral and bacterial pathogenesis.Folia microbiologica · 2025Review
- Review: Knowledge Gained and Gaps in Understanding in the 25 Years Since Human Metapneumovirus Was First Identified as a Cause of Human Disease.The Journal of infectious diseases · 2025Review
- Clinical Features and Gene Expression Patterns in Adults Hospitalized With Respiratory Syncytial Virus and Human Metapneumovirus Infection.The Journal of infectious diseases · 2025Article
- Vaccine Development for Human Pneumoviruses.Vaccines · 2025Review
- A Case of Severe Respiratory Failure Caused by Metapneumovirus and Influenza Virus in a Patient with HIV Infection.Viruses · 2025Article
- The Role of Gut Microbiota in the Modulation of Pulmonary Immune Response to Viral Infection Through the Gut-Lung Axis.Journal of inflammation research · 2025Review
- Distinct roles for type I and type III interferons in virulent human metapneumovirus pathogenesis.PLoS pathogens · 2024Article
- Effects of G and SH Truncation on the Replication, Virulence, and Immunogenicity of Avian Metapneumovirus.Vaccines · 2024Article
- LAG-3 Contribution to T Cell Downmodulation during Acute Respiratory Viral Infections.Viruses · 2023Review
- Pediatric burden and seasonality of human metapneumovirus over 5 years in Managua, Nicaragua.Influenza and other respiratory viruses · 2022Article
- A chimeric influenza virus vaccine expressing fusion protein epitopes induces protection from human metapneumovirus challenge in mice.Frontiers in microbiology · 2022Article
- Review
- Report of death in children with SARS-CoV-2 and human metapneumovirus (hMPV) coinfection: Is hMPV the trigger?Journal of medical virology · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, as a leading agent of acute respiratory tract infections in children <5 years of age and the elderly, the human metapneumovirus (HMPV) has gained considerable attention. As inferred from studies comparing vaccinated and experimentally infected mice, the acquired immune response elicited by this pathogen fails to efficiently clear the virus from the airways, which leads to an exaggerated inflammatory response and lung damage. Furthermore, after disease resolution, there is a poor development of T and B cell immunological memory, which is believed to promote reinfections and viral spread in the community. In this article, we discuss the molecular mechanisms that shape the interactions of HMPV with host tissues that lead to pulmonary pathology and to the development of adaptive immunity that fails to protect against natural infections by this virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.